// App-Quantinova.ai

TPS5103 : DASL-HiCaP Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)—A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.

Researchers

Presenter

  • Tamim Niazi

Principal Investigators

  • Scott Williams

  • Ian D. Davis

  • Martin R. Stockler

  • Andrew James Martin

  • Karen Bracken

  • Felicia Roncolato

  • Lisa Horvath

  • Shomik Sengupta

  • Jarad Martin

  • Tee Lim

  • Simon Hughes

  • Raymond S. McDermott

  • James W.F. Catto

  • Paul J. Kelly

  • Wendy R. Parulekar

  • Scott Carlyle Morgan

  • Ricardo A. Rendon

  • Christopher Sweeney

Medical Centers

  • Jewish General Hospital/ McGill Univeristy, Montreal, QC, Canada

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Division of Cancer Medicine, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia

  • Eastern Health Clinical School, Monash University, Box Hill, VIC, Australia

  • NHMRC Clinical Trials Centre, The University of Sydney, Sydney, Australia

  • NHMRC Clinical Trials Centre, The University of Sydney, Sydney, Australia

  • NHMRC Clinical Trials Centre, The University of Sydney, Sydney, Australia

  • NHMRC Clinical Trials Centre, The University of Sydney, Sydney, Australia

  • Sydney Cancer Centre, Sydney, Australia

  • Austin Health, Melbourne, Australia

  • Calvary Mater Newcastle, Newcastle, Australia

  • Fiona Stanley Hospital, Perth, Australia

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • St Vincent's University Hospital, Dublin, Ireland

  • Department of Oncology & Metabolism, University of Sheffield, Sheffield, United Kingdom

  • Cork University Hospital, Cork, Ireland

  • Canadian Cancer Trials Group, Kingston, ON, Canada

  • The Ottawa Hospital Research Institute, Ottawa, ON, Canada

  • Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada

  • Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA

Locations

  • Canada

  • United States

  • Australia

  • United Kingdom

  • Ireland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Docetaxel

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • NCT04136353

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved